Newsletter July 2023 No.216
Top News
"JPMA President's Press Conference" Held; New President Hiroaki Ueno Delivers Policy Address
On May 25, 2023, the “JPMA Chairman’s Press Conference” was held at Bellesalle Iidabashi Ekimae (Chiyoda Ward, Tokyo).At this press conference, newly elected Chairman Hiroaki Ueno, who was appointed at the “268th JPMA Assembly” held on the same day, delivered his policy address. Under the theme “Toward a Nation Where Innovation Thrives,” he discussed the challenging environment facing the pharmaceutical industry and the initiatives on which the JPMA will focus moving forward.The press conference was held in a hybrid format, combining in-person and online participation. Twenty-nine members of the media from 22 companies attended, and a lively question-and-answer session took place, reflecting the high level of interest in the future direction of the pharmaceutical industry. Below is a summary of Chairman Ueno’s remarks and the Q&A session.
Topics
- The 12th Asian Pharmaceutical Association Collaboration Conference (APAC) - Bringing Innovative Medicines to the People of Asia Quickly
- Joint Symposium with the Joint Meeting of the Japanese Society of Infectious Diseases/Japanese Society of Chemotherapy" was held.
Bringing Antimicrobial Agents from Japan to the World Again! Building a Drug Discovery Ecosystem through Industry-Academia-Government Collaboration - JPMA Media Forum: What to do about Vaccines? -What can we do now for the future?
- JPMA Media Forum on Health and Economy "The Future of Health Economics Research in Japan's Aging Society, a Global Focus
- Joint Assembly of Drug Evaluation Committee and Regulatory Affairs Committee for FY2023
Policy Research Institute
Trends in medical record integration as seen in the case of COVID-19
From JPMA
Upon Assuming the Presidency — Aiming for a Nation Where Innovation Thrives —